Oral Or Topial Administration Of Compound Selected From Dihydroxy Vitamin D3, Etretinate, Diltiazem And Anthralin


Ontology type: sgo:Patent     


Patent Info

DATE

1999-07-20T00:00

AUTHORS

HENG MADALENE C Y

ABSTRACT

An improved method of treating psoriasis involves controlling the enhanced proliferation and terminal differentiation of psoriatic epidermis through the activity of epidermal phosphorylase kinase. In general, the method involves contacting psoriatic epidermal cells with a combination of substances affecting the activity of phosphorylase kinase. The combination can be: (1) a calmodulin inhibitor together with a stimulator of cAMP-dependent protein kinase II, (2) a calmodulin inhibitor together with a calcium channel blocker; (3) a stimulator of cAMP-dependent protein kinase II together with a calcium channel blocker; or (4) a calmodulin inhibitor together with a calcium channel blocker and a stimulator of cAMP-dependent protein kinase II. Alternatively, a selective phosphorylase kinase inhibitor such as curcumin can be administered, alone or with an agent such as vitamin D3 or an analogue thereof, etretinate, diltiazem, or anthralin. The invention also includes pharmaceutical compositions. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "HENG MADALENE C Y", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/296613a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035034012", 
          "https://doi.org/10.1038/296613a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1999-07-20T00:00", 
    "description": "

An improved method of treating psoriasis involves controlling the enhanced proliferation and terminal differentiation of psoriatic epidermis through the activity of epidermal phosphorylase kinase. In general, the method involves contacting psoriatic epidermal cells with a combination of substances affecting the activity of phosphorylase kinase. The combination can be: (1) a calmodulin inhibitor together with a stimulator of cAMP-dependent protein kinase II, (2) a calmodulin inhibitor together with a calcium channel blocker; (3) a stimulator of cAMP-dependent protein kinase II together with a calcium channel blocker; or (4) a calmodulin inhibitor together with a calcium channel blocker and a stimulator of cAMP-dependent protein kinase II. Alternatively, a selective phosphorylase kinase inhibitor such as curcumin can be administered, alone or with an agent such as vitamin D3 or an analogue thereof, etretinate, diltiazem, or anthralin. The invention also includes pharmaceutical compositions.

", "endDate": "2014-01-10", "id": "sg:patent.US-5925376-A", "name": "ORAL OR TOPIAL ADMINISTRATION OF COMPOUND SELECTED FROM DIHYDROXY VITAMIN D3, ETRETINATE, DILTIAZEM AND ANTHRALIN", "sameAs": [ "https://app.dimensions.ai/details/patent/US-5925376-A" ], "sdDataset": "patents", "sdDatePublished": "2022-09-02T16:21", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/patent/patent_43.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-5925376-A'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-5925376-A'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-5925376-A'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-5925376-A'


 

This table displays all metadata directly associated to this object as RDF triples.

28 TRIPLES      14 PREDICATES      16 URIs      9 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-5925376-A schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author N4b39714b1e64414abd7f917cd466cc36
4 schema:citation sg:pub.10.1038/296613a0
5 schema:datePublished 1999-07-20T00:00
6 schema:description <p>An improved method of treating psoriasis involves controlling the enhanced proliferation and terminal differentiation of psoriatic epidermis through the activity of epidermal phosphorylase kinase. In general, the method involves contacting psoriatic epidermal cells with a combination of substances affecting the activity of phosphorylase kinase. The combination can be: (1) a calmodulin inhibitor together with a stimulator of cAMP-dependent protein kinase II, (2) a calmodulin inhibitor together with a calcium channel blocker; (3) a stimulator of cAMP-dependent protein kinase II together with a calcium channel blocker; or (4) a calmodulin inhibitor together with a calcium channel blocker and a stimulator of cAMP-dependent protein kinase II. Alternatively, a selective phosphorylase kinase inhibitor such as curcumin can be administered, alone or with an agent such as vitamin D3 or an analogue thereof, etretinate, diltiazem, or anthralin. The invention also includes pharmaceutical compositions.</p>
7 schema:endDate 2014-01-10
8 schema:name ORAL OR TOPIAL ADMINISTRATION OF COMPOUND SELECTED FROM DIHYDROXY VITAMIN D3, ETRETINATE, DILTIAZEM AND ANTHRALIN
9 schema:sameAs https://app.dimensions.ai/details/patent/US-5925376-A
10 schema:sdDatePublished 2022-09-02T16:21
11 schema:sdLicense https://scigraph.springernature.com/explorer/license/
12 schema:sdPublisher N31002196e08643cebf68c9ee22a8331f
13 sgo:license sg:explorer/license/
14 sgo:sdDataset patents
15 rdf:type sgo:Patent
16 N31002196e08643cebf68c9ee22a8331f schema:name Springer Nature - SN SciGraph project
17 rdf:type schema:Organization
18 N4b39714b1e64414abd7f917cd466cc36 rdf:first N8e248ef77b9047b6b8ed42916c7fec44
19 rdf:rest rdf:nil
20 N8e248ef77b9047b6b8ed42916c7fec44 schema:name HENG MADALENE C Y
21 rdf:type schema:Person
22 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
23 rdf:type schema:DefinedTerm
24 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
25 rdf:type schema:DefinedTerm
26 sg:pub.10.1038/296613a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035034012
27 https://doi.org/10.1038/296613a0
28 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...